Hai Zheng Pharmaceutical: Injection of Ipratropium Bromide Hydrochloride Passes Generic Drug Consistency Evaluation

On March 26, Hai Zheng Pharmaceutical announced that its wholly-owned subsidiary Hanhui Pharmaceutical Co., Ltd. has received the Approval Notice for the Supplementary Application of Injection of Idarubicin Hydrochloride issued by the National Medical Products Administration. This drug has passed the evaluation of generic drug quality and efficacy consistency. Injection of Idarubicin Hydrochloride is applicable for the induction and remission of acute non-lymphocytic leukemia in adults who have not been treated, as well as the induction and remission of relapsed and refractory ANLL in adults. It is also used as second-line treatment for acute lymphoblastic leukemia in adults and children. The original drug is developed by Pfizer.